Vascular Biology Unit, School of Medicine, James Cook University, Townsville, Queensland 4811, Australia.
Atherosclerosis. 2010 Sep;212(1):16-29. doi: 10.1016/j.atherosclerosis.2010.02.008. Epub 2010 Mar 6.
Abdominal aortic aneurysm (AAA) is a common disease associated with significant cardiovascular morbidity and mortality. The pathogenesis of AAA is poorly defined, making targeting of new therapies problematic. Current evidence favours an interaction of multiple environmental and genetic factors in the initiation and progression of AAA. Epigenetics is the term used to define the properties of the genome that are not explained by the primary sequence, but are due to the modifications of DNA and/or associated proteins. Previous research indicates the association of gene specific promoter DNA hyper-methylation and global DNA hypo-methylation with atherosclerosis. Evidence also suggests an important role for epigenetic processes such as histone acetylation in cardiovascular diseases including atherosclerosis and restenosis. Altered DNA methylation or histone acetylation occur in inflammation, cellular proliferation and remodelling processes and therefore maybe relevant to the pathology of AAA. Important risk factors for AAA, including cigarette smoking, older age, male gender and hypertension, have been linked with epigenetic effects and thus could act in this way to promote AAA. In this review, we discuss the potential role of epigenetic mechanisms in AAA. Since epigenetic alterations are to some extent reversible, further study of this area may identify new treatment targets for AAA.
腹主动脉瘤(AAA)是一种常见的疾病,与显著的心血管发病率和死亡率相关。AAA 的发病机制尚未明确,这使得新疗法的靶向治疗变得复杂。目前的证据倾向于认为,多种环境和遗传因素在 AAA 的发生和发展中相互作用。表观遗传学是一个术语,用于定义基因组的特性,这些特性不能用原始序列来解释,而是由于 DNA 和/或相关蛋白的修饰。先前的研究表明,基因特异性启动子 DNA 高甲基化和全基因组 DNA 低甲基化与动脉粥样硬化有关。证据还表明,表观遗传过程(如组蛋白乙酰化)在心血管疾病(包括动脉粥样硬化和再狭窄)中起着重要作用。在炎症、细胞增殖和重塑过程中会发生 DNA 甲基化或组蛋白乙酰化的改变,因此可能与 AAA 的病理学有关。AAA 的重要危险因素,包括吸烟、年龄较大、男性和高血压,与表观遗传效应有关,因此可能以这种方式促进 AAA。在这篇综述中,我们讨论了表观遗传机制在 AAA 中的潜在作用。由于表观遗传改变在某种程度上是可逆的,因此对这一领域的进一步研究可能会为 AAA 确定新的治疗靶点。